Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Apalutamide in Severe Hepatic Impairment
NCT04154774Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Area Under Concentration-time Curve from Time 0 to Infinite Time, Area Under Concentration-time Curve from Time 0 to the Time of the Last Concentration and 1 more. Started Nov 2019; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04154774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154774.